Skip to content

Immuneering Corporation

IMRX

CIK 0001790340

← back to feed
Revenue (TTM)
$38.38K
−100.0% YoY Q1 Mar 2026
Net Income (TTM)
−$57.91M
+8.2% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$1.41
+37.7% YoY Q1 Mar 2026
Gross Margin
49.6%
Q1 Mar 2026
Operating Margin
-158,828.3%
Q1 Mar 2026
Net Margin
-150,874.9%
Q1 Mar 2026
Free Cash Flow (TTM)
−$62.58M
Q1 Mar 2026
Cash
$47.32M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
25.94M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings